Immunoglobulin 4-related disease (IgG4-RD) is known for its potential to affect nearly every organ, particularly a preference for large and middle-sized arteries when vascular involvement occurs.
Visit the Investors and Media section of Mirum's corporate website for webcast links and additional information. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases ...
For further financial information for the period ended September 30, 2024, please refer to the Q3 financial report filing. About Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC) ...
Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) will be releasing its earnings data before the market opens on Thursday, November 14th. Analysts expect Chemomab Therapeutics to post earnings of ...
Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have earned an average recommendation of “Buy” from the nine analysts that are covering the firm, Marketbeat Ratings reports. Eight ...
Mirum Pharmaceuticals, Inc. today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November ...